Molecure - Crunchbase Company Profile & Funding

Q: Where is Molecure's headquarters?

Molecure is located in Warsaw, Mazowieckie, Poland.

Q: When was the last funding round for Molecure?

Molecure closed its last funding round on obfuscated from a Post-IPO Secondary round.

Q: How much funding has Molecure raised to date?

Molecure has raised obfuscated.

Overview

Molecure

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

See more interactive data and historical milestones on desktop for the best experience

About Molecure

CB Rank

193490

Molecure is an innovative biopharmaceutical company that specializes in discovery, development, and commercialization of novel therapeutics.

Founded

obfuscation

Public

Post-IPO Secondary

Warsaw, Mazowieckie, Poland

51-100

molecure.com

Biopharma

Biotechnology

Therapeutics

Funding Rounds

Post-IPO Secondary

OBF

obfuscation

Key People

Adam Golebiowski: Founder and Senior Research Fellow

Details

Legal Name

Molecure SA

Operating Status

Active

Stock Symbol

WSE:MOC

Company Type

For Profit

Founders

Adam Golebiowski

About the Company

Molecure is an innovative biopharmaceutical company that specializes in the discovery, development, and commercialization of novel therapeutics for inflammatory diseases.

Phone Number

+48 22 552 67 24

Contact Email

contact@molecure.com

Predictions & Insights

Products & Services

OATD-01

An oral, first-in-class chitotriosidase 1 (CHIT1) inhibitor for treating interstitial lung diseases like sarcoidosis and idiopathic pulmonary fibrosis.

OATD-02

An oral, selective dual arginase inhibitor targeting ARG1 and ARG2 enzymes for cancer treatment.

Research & Development

Molecure is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated

...

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Post-IPO Secondary - Molecure	—	obfuscated obfuscation	—	Post-IPO Secondary
obfuscated obfuscation	Post-IPO Secondary - Molecure	—	obfuscated obfuscation	—	Post-IPO Secondary
obfuscated obfuscation	Post-IPO Secondary - Molecure	—	obfuscated obfuscation	—	Post-IPO Secondary
obfuscated obfuscation	Post-IPO Secondary - Molecure	—	obfuscated obfuscation	—	Post-IPO Secondary
obfuscated obfuscation	Post-IPO Secondary - Molecure	—	obfuscated obfuscation	—	Post-IPO Secondary

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Post-IPO Secondary - Molecure	—	obfuscated obfuscation	—	Post-IPO Secondary
obfuscated obfuscation	Post-IPO Secondary - Molecure	—	obfuscated obfuscation	—	Post-IPO Secondary
obfuscated obfuscation	Post-IPO Secondary - Molecure	—	obfuscated obfuscation	—	Post-IPO Secondary
obfuscated obfuscation	Post-IPO Secondary - Molecure	—	obfuscated obfuscation	—	Post-IPO Secondary
obfuscated obfuscation	Post-IPO Secondary - Molecure	—	obfuscated obfuscation	—	Post-IPO Secondary